Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs


Taxes, Tariffs & Access to Medicine

Poor countries have long claimed that their people suffer needless sickness and death because the price of medicines is too high. They are right. But often part of the fault lies in their own policies, which jack up prices by taxing medicines, raw materials for drugs and medical devices.

Mapping the AIDS epidemic

It's no secret that AIDS is a major problem on the African continent, but a series of cartograms designed by a University of Michigan Professor provides an effective visual demonstration of this problem by converting topographic areas into statistical proportions.

Spain joins IFFIm

On Friday, Spain approved a $240 million donation to GAVI's International Finance Facility for Immunization. Other IFFIm donors include France, Italy, Norway, Sweden, the United Kingdom, Brazil and South Africa.

IFFIm Overview (from Vaccines for Development):

FDA Tentatively Approves Generic Drugs for Use by PEPFAR

The New York Times today detailed the FDA's recent tentative approval of a generic 3-in-1 combination anti-retrovival drug made by the Indian manufacturer Aurobindo Pharma. This decision follows on the heels of another approval last week (that one for a generic version of GlaxoSmithKline's Epivir ARV) and opens the door for the purchase and use of the drugs in PEPFAR-supported programs in developing countries.

The PMI Turns One - How Will We Measure Success?

In a July 1 editorial, the Lancet (free registration required) praised the US President's Malaria Initiative (PMI) which was celebrating the one year anniversary of its founding. Although much quieter than its older brother, PEPFAR, the PMI has slowly and softly helped revolutionize the battle against malaria by concentrating resources to make substantial gains against the disease. However, this model is not without its critics. According to the article: